Background SLE is a complex autoimmune condition requiring evaluation across disease activity, permanent damage and ...

Objective Systemic lupus erythematosus Prospective Observational Cohort Study (SPOCS) was a prospective observational study ...

Objective To assess the effectiveness of belimumab (BEL) in improving anaemia, thrombocytopenia, lymphopenia and leucopenia in patients with SLE. Conclusion In this real-world cohort, BEL treatment ...

Objective The comparative safety of immunosuppressive drugs, biologicals and glucocorticoids (GC) for patients with SLE remains controversial. We aimed to investigate the specific side effects of the ...

Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been approved as add-on therapies for SLE in China. The aim of this study is to ...

Objective Corticosteroids are a mainstay of SLE treatment; however, cumulative steroid exposure may lead to organ damage. This study aimed to quantify the risk of new diabetes, hypertension, cataracts ...

Objective Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterised by venous thrombosis (VT) or arterial thrombosis (AT) and/or pregnancy morbidity and the presence of ...

Objective Systemic lupus erythematosus (SLE) is associated with increased risk for adverse pregnancy outcomes (APOs). The Predictors of Pregnancy Outcomes: Biomarkers in Antiphospholipid Syndrome and ...

Objectives Genetic variation within the human leukocyte antigen (HLA) region influences susceptibility across systemic autoimmune diseases (SADs). We investigated HLA class I and II allelic ...

Objective This study explored the relationship between clinical phenotypes and immuno-molecular features of systemic lupus erythematosus (SLE) using unsupervised machine learning and multi-omics ...